Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
17
AIM Quote, Financials, Valuation and Earnings
Last price:
$0.20
Seasonality move
:
17.73%
Day range:
$0.19 - $0.20
52-week range:
$0.16 - $0.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
52.22x
P/B ratio:
4.16x
Volume:
336K
Avg. volume:
636.1K
1-year change:
-60.82%
Market cap:
$12.1M
Revenue:
$202K
EPS (TTM):
-$0.47
Analysts' Opinion
-
Consensus RatingAIM ImmunoTech has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, AIM ImmunoTech has an estimated upside of 1347.37% from its current price of $0.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.19.
Fair Value
-
According to the consensus of 0 analysts, AIM ImmunoTech has 1347.37% upside to fair value with a price target of -- per share.
AIM vs. S&P 500
-
Over the past 5 trading days, AIM ImmunoTech has underperformed the S&P 500 by -11.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AIM ImmunoTech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AIM ImmunoTech revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter AIM ImmunoTech reported revenues of $35K.
Earnings Growth
-
AIM ImmunoTech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AIM ImmunoTech reported earnings per share of -$0.06.
Enterprise value:
7.6M
EV / Invested capital:
1.35x
Price / LTM sales:
52.22x
EV / EBIT:
--
EV / Revenue:
40.18x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-0.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$154K
Return On Assets:
-129.02%
Net Income Margin (TTM):
-12594.21%
Return On Equity:
-256.33%
Return On Invested Capital:
-219.06%
Operating Margin:
-12825.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $134K | $193K | $190K | $46K | $35K | |
| Gross Profit | -$188K | $163K | $154K | $16K | $27K | |
| Operating Income | -$20M | -$23.5M | -$27.9M | -$8.2M | -$4.5M | |
| EBITDA | -$20.1M | -$21.6M | -$26.2M | -$7.8M | -$3.4M | |
| Diluted EPS | -$0.43 | -$0.43 | -$0.47 | -$0.16 | -$0.06 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.8M | $38M | $41.2M | $22.7M | $7.6M | |
| Total Assets | $64.2M | $63.1M | $46.3M | $27.9M | $13.6M | |
| Current Liabilities | $795K | $767K | $2.9M | $4.7M | $10.1M | |
| Total Liabilities | $3.1M | $1M | $3.6M | $5.3M | $10.7M | |
| Total Equity | $61.1M | $62M | $42.7M | $22.6M | $2.9M | |
| Total Debt | $226K | -- | -- | -- | $2.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.8M | -$17.6M | -$20.7M | -$5.7M | -$3.1M | |
| Cash From Investing | $8M | $2.7M | $788K | -$336K | $334K | |
| Cash From Financing | $205K | $338K | $5.6M | $233K | $137K | |
| Free Cash Flow | -$16M | -$18.1M | -$21.3M | -$5.9M | -$3.3M | |
AIM
Sector
Market Cap
$12.1M
$43.9M
Price % of 52-Week High
30.65%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-9.81%
-0.74%
1-Year Price Total Return
-60.83%
-29.11%
Beta (5-Year)
-0.363
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.21
200-day SMA
Sell
Level
$0.34
Bollinger Bands (100)
Sell
Level
0.22 - 0.32
Chaikin Money Flow
Sell
Level
-444.8M
20-day SMA
Sell
Level
$0.21
Relative Strength Index (RSI14)
Sell
Level
35.50
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-90.3614
50-day SMA
Sell
Level
$0.23
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
571.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-33.1774)
Sell
CA Score
(Annual)
Level (-3.8304)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.5868)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Stock Forecast FAQ
In the current month, AIM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AIM average analyst price target in the past 3 months is --.
-
Where Will AIM ImmunoTech Stock Be In 1 Year?
According to analysts, the consensus estimate is that AIM ImmunoTech share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About AIM ImmunoTech?
Analysts are divided on their view about AIM ImmunoTech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AIM ImmunoTech is a Sell and believe this share price will drop from its current level to --.
-
What Is AIM ImmunoTech's Price Target?
The price target for AIM ImmunoTech over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AIM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AIM ImmunoTech is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AIM?
You can purchase shares of AIM ImmunoTech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AIM ImmunoTech shares.
-
What Is The AIM ImmunoTech Share Price Today?
AIM ImmunoTech was last trading at $0.20 per share. This represents the most recent stock quote for AIM ImmunoTech. Yesterday, AIM ImmunoTech closed at $0.19 per share.
-
How To Buy AIM ImmunoTech Stock Online?
In order to purchase AIM ImmunoTech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
